New York, Palo Alto, and San Diego – Paul Hastings LLP, a leading global law firm, announced today that the firm advised Merck Animal Health, a division of Merck & Co., Inc., on its acquisition of the U.S. rights to SENTINEL® FLAVOR TABS® and SENTINEL® SPECTRUM® Chews from Virbac for $400 million.
The transaction further solidifies Merck Animal Health’s position in the U.S. Companion Animal Health category, pairing the SENTINEL branded products with Merck Animal Health’s BRAVECTO® product line for comprehensive, continuous parasite protection.
The closing of the transaction is subject to antitrust clearance and other customary closing conditions and is expected to close by mid-year 2020.
The Paul Hastings team was led by Corporate partner David Shine, and included partners Todd Schneider, Charles Patrizia, and Eric Keller, and associates Ryan Enchelmayer, Joseph Eno, Tyler Thiret, and Matthew Tippett.
At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.